Trial Profile

Remission induction in very early rheumatoid arthritis: a comparison of etanercept plus methotrexate plus steroid with standard therapy

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etanercept (Primary) ; Hydroxychloroquine; Methotrexate; Methylprednisolone acetate; Methylprednisolone acetate; Sulfasalazine
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms RIVERA

Most Recent Events

27 Jul 2020 This trial is completed in UK (Global End Date: 30 May 2010), according to European Clinical Trials Database record.
01 Dec 2015 Status changed from completed to discontinued as reported by ISRCTN: Current Controlled Trials.
25 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com